SCHEMBL2928219

SCHEMBL2928219

CC(C)(C)OC(=O)NCCC[C@@H](C(N)=O)N(C(=O)OCC1c2ccccc2-c2ccccc21)C(Cc1ccccc1)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.42
PAX8 Q06710 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
TPSAB1 Q15661 2/20 0.37
TPSD1 Q9BZJ3 2/20 0.37
TPSG1 Q9NRR2 2/20 0.37
TLR2 O60603 1/20 0.37
TLR1 Q15399 1/20 0.37
MDM2 Q00987 1/20 0.37
IDO1 P14902 1/20 0.36
MEN1 O00255 2/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 2/20 0.36
ALDH1A1 P00352 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
POLB P06746 1/20 0.36
MAPK1 P28482 1/20 0.36
PTPN1 P18031 1/20 0.35
MMP1 P03956 1/20 0.35
MMP3 P08254 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2926699 0.88 KMT2A (0.41) KMT2APAX8TDP1TLR2TLR1
SCHEMBL2924241 0.80 KMT2A (0.41) KMT2APAX8TDP1TPSAB1TPSD1
SCHEMBL30685999 0.80 KMT2A (0.48) KMT2ATPSAB1TPSD1TPSG1TLR2
SCHEMBL30074816 0.80 KMT2A (0.48) KMT2ATPSAB1TPSD1TPSG1TLR2
SCHEMBL25354991 0.78 KMT2A (0.50) KMT2ATPSAB1TPSD1TPSG1TLR2
SCHEMBL29401577 0.78 KMT2A (0.50) KMT2ATPSAB1TPSD1TPSG1TLR2
SCHEMBL25354987 0.78 KMT2A (0.50) KMT2ATPSAB1TPSD1TPSG1TLR2
SCHEMBL31688635 0.77 KMT2A (0.52) KMT2ATPSAB1TPSD1TPSG1TLR2
SCHEMBL2922999 0.77 KMT2A (0.38) KMT2ATPSAB1TPSD1TPSG1TLR2
SCHEMBL7596306 0.75 MAPT (0.47) TPSAB1TPSD1TPSG1MAPTKLK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1675824-B1 SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND ANTAGONISTS WURSTER SIEGFRIED (FI) 2010-09-29 EP disclosed
US-7741362-B2 Somatostatin receptor 1 and/or 4 selective agonists and antagonists SIEGFRIED WURSTER (FI) 2010-06-22 US disclosed
US-20100004339-A1 Somatostatin Receptor 1 and/or 4 Selective Agonists and Antagonists OY JUVANTIA PHARMA LTD. (FI) 2010-01-07 US disclosed
US-20070129422-A1 Somatostatin receptor 1 and/or 4 selective agonists and antagonists OY JUVANTIA PHARMA LTD (FI) 2007-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129422-A1 Somatostatin receptor 1 and/or 4 selective agonists and antagonists SSTR4, SSTR1, SSTR3 KMT2A 2112/4885PAX8 3352/4885TDP1 4012/4885
US-20100004339-A1 Somatostatin Receptor 1 and/or 4 Selective Agonists and Antagonists SSTR4, SSTR1, SSTR3 KMT2A 2112/4885PAX8 3352/4885TDP1 4012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.